Medical Genetics Division, Shizuoka Cancer Center Research Institute, Sunto-gun, Shizuoka, 411-8777, Japan.
Cancer Diagnostics Research Division, Shizuoka Cancer Center Research Institute, Sunto-gun, Shizuoka, 411-8777, Japan.
BMC Cancer. 2021 Feb 19;21(1):181. doi: 10.1186/s12885-021-07899-1.
Mutation analysis using next-generation sequencing highlights the features of tumors with somatic alterations. However, the mutation profile of double cancer remains unclear. Here, we analyzed tumors derived from the same patient using whole exome sequencing (WES) to investigate the coherence of somatic mutations in double cancer.
First, the tumor mutational burden (TMB) was investigated using WES of 5521 tumor specimens from a Japanese pan-cancer cohort. The frequencies of mutation concordance were then compared in these cancers. Finally, we calculated the expected value of mutational concordance fitting a Poisson distribution to determine the relationship between double and metastatic cancers.
In all, 44, 58, and 121 paired samples were diagnosed as double cancer, multifocal lesions (derived from identical tissues), and metastasis, respectively. Our analysis revealed that common somatic mutations were almost entirely absent in double cancer, whereas primary tumors and metastatic foci harbored several identical alterations. Concordance of the mutation profile in the same patient reflects the tumor origin and development, suggesting the potential for identifying double cancer based on common somatic mutations. Furthermore, according to a Poisson distribution, double cancer could be discriminated based on paired samples from the same patient. The probability of double cancer with more than 10 mutations was ≤1 part-per-billion (ppb, 10). In multifocal lesions, 74% of tumor pairs accumulated ≤10 common mutations, implying a difference in tumor origin within identical tissues.
These findings indicate that counting common somatic mutations can indicate the differences in origin between tumors derived from the same patient. Our mutation coherence analysis can thus provide beneficial information for diagnosing double cancer.
使用下一代测序进行突变分析突出了具有体细胞改变的肿瘤的特征。然而,双癌的突变谱尚不清楚。在这里,我们使用全外显子组测序(WES)分析来自同一患者的肿瘤,以研究双癌中体细胞突变的一致性。
首先,使用 WES 分析了来自日本泛癌队列的 5521 个肿瘤标本的肿瘤突变负担(TMB)。然后比较了这些癌症中突变一致性的频率。最后,我们计算了符合泊松分布的突变一致性的期望值,以确定双癌和转移性癌症之间的关系。
总共诊断出 44、58 和 121 对双癌、多灶性病变(源自相同组织)和转移的配对样本。我们的分析表明,双癌中几乎完全不存在常见的体细胞突变,而原发性肿瘤和转移灶则存在多个相同的改变。同一患者中突变谱的一致性反映了肿瘤的起源和发展,表明有可能基于常见的体细胞突变来识别双癌。此外,根据泊松分布,可以根据来自同一患者的配对样本来区分双癌。具有超过 10 个突变的双癌的概率≤10 亿分之一(ppb,10)。在多灶性病变中,74%的肿瘤对累积≤10 个常见突变,这意味着同一组织内肿瘤起源存在差异。
这些发现表明,计数常见的体细胞突变可以指示来自同一患者的肿瘤之间起源的差异。因此,我们的突变一致性分析可以为诊断双癌提供有益的信息。